Command Palette

Search for a command to run...

PPLPHARMA

208.29+2.44%
Market Cap
₹24,963.28 Cr
Stock P/E
34.71
ROCE
6.61%
ROE
1.14%
Book Value
₹59.59

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

Financials

YoY Net Sales
EPS Growth
Operating Margin

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Piramal Pharma Ltd. operates in a competitive pharmaceuticals market characterized by significant variations in growth, profitability, and valuation among peers. While Piramal shows moderate growth and profitability metrics, some competitors demonstrate superior performance, making them potential leaders in the sector. However, Piramal's metrics suggest it is positioned well relative to the market, offering a balance between growth and valuation.

Key Points
  • Piramal Pharma shows strong revenue growth but lower profitability compared to top competitors.
  • Financially, Piramal has moderate debt levels but could improve its return metrics.
  • Compared to peers, Piramal is reasonably valued, making it an attractive option for growth-focused investors.
Top Performers
Cipla Ltd.

Highest ROE and strong revenue growth, indicating both profitability and efficiency.

Dr. Reddy's Laboratories Ltd.

Strong profitability metrics with low valuation ratios, making it a compelling pick.

Mankind Pharma Ltd.

Exceptional revenue growth and good profitability, marking it as a standout performer.